Pergolide protects dopaminergic neurons in primary culture under stress conditions

Gille, G.; Rausch, W.-D.; Hung, S.-T.; Moldzio, R.; Janetzky, B.; Hundemer, H. P.; Kolter, T.; Reichmann, H.
May 2002
Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p633
Academic Journal
Summary. Dopamine agonists are an important therapeutic strategy in the treatment of Parkinson's disease. They postpone the necessity for and reduce the required dose of L-3,4-dihydroxyphenylalanine (L-DOPA) medication thus protecting against the development of motor complications and potential oxidative stress due to L-DOPA metabolism. In primary cultures from mouse mesencephalon we show that pergolide, a preferential D2 agonist enhanced the survival of healthy dopaminergic neurons at low concentrations of 0.001 μM. About 100 fold higher concentrations (0.1 μM) were necessary to partially reverse the toxic effects of 10 μM 1-methyl-4-phenylpyridinium (MPP+). Pergolide was equally effective in preventing the reduction of dopamine uptake induced by 200 μM L-DOPA. Furthermore, between 0.001–0.1 μM it also reduced lactate production thus promoting aerobic metabolism. The present findings suggest that pergolide protects dopaminergic neurons under conditions of elevated oxidative stress.


Related Articles

  • Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. Ganat, Yosif M.; Calder, Elizabeth L.; Kriks, Sonja; Nelander, Jenny; Tu, Edmund Y.; Jia, Fan; Battista, Daniela; Harrison, Neil; Parmar, Malin; Tomishima, Mark J.; Rutishauser, Urs; Studer, Lorenz // Journal of Clinical Investigation;Jul2012, Vol. 122 Issue 7, p1 

    Embryonic stem cells (ESCs) represent a promising source of midbrain dopaminergic (DA) neurons for applications in Parkinson disease. However, ESC-based transplantation paradigms carry a risk of introducing inappropriate or tumorigenic cells. Cell purification before transplantation may...

  • The Midbrain Dopaminergic System: Anatomy and Genetic Variation in Dopamine Neuron Number of Inbred Mouse Strains. Zaborszky, Laszlo; Vadasz, Csaba // Behavior Genetics;Jan2001, Vol. 31 Issue 1, p47 

    The mesotelencephalic dopamine system is genetically variable and affects motor behavior, motivation, and learning. Here we examine the genetic variation of mesencephalic DA neuron number in a quasi-congenic RQI mouse strain and its background partner and in a recombinant inbred strain with...

  • K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration. Schiemann, Julia; Schlaudraff, Falk; Klose, Verena; Bingmer, Markus; Seino, Susumu; Magill, Peter J; Zaghloul, Kareem A; Schneider, Gaby; Liss, Birgit; Roeper, Jochen // Nature Neuroscience;Sep2012, Vol. 15 Issue 9, p1272 

    Phasic activation of the dopamine (DA) midbrain system in response to unexpected reward or novelty is critical for adaptive behavioral strategies. This activation of DA midbrain neurons occurs via a synaptically triggered switch from low-frequency background spiking to transient high-frequency...

  • Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Rojas, P.; Joodmardi, E.; Hong, Y.; Perlmann, T.; Ögren, S. O // Molecular Psychiatry;Aug2007, Vol. 12 Issue 8, p756 

    The transcription factor Nurr1 (NR4A2) has been found to play a critical role in the development of midbrain dopaminergic neurons. Nurr1 heterozygous (+/−) male and female mice expressing 35–40% of normal levels of Nurr1 were generated and examined in animal models related to...

  • Continuous dopaminergic stimulation and novel formulations of dopamine agonists. Stocchi, Fabrizio // Journal of Neurology;May2011, Vol. 258 Issue 2, p316 

    There is now accumulating evidence that the combination of progressive pathology of Parkinson's disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors are the key contributing factors to the priming...

  • Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons. Aguirre, Pabla; Mena, Natalia P.; Carrasco, Carlos M.; Muñoz, Yorka; Pérez-Henríquez, Patricio; Morales, Rodrigo A.; Cassels, Bruce K.; Méndez-Gálvez, Carolina; García-Beltrán, Olimpo; González-Billault, Christian; Núñez, Marco T. // PLoS ONE;12/14/2015, Vol. 10 Issue 12, p1 

    Neuronal death in Parkinson’s disease (PD) is often preceded by axodendritic tree retraction and loss of neuronal functionality. The presence of non-functional but live neurons opens therapeutic possibilities to recover functionality before clinical symptoms develop. Considering that iron...

  • Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson's disease. Zhao, Hong; Xu, Mei-Ling; Zhang, Qi; Guo, Zhao-Hui; Peng, Ying; Qu, Zheng-Yi; Li, Yong-Nan // Neurological Sciences;Dec2014, Vol. 35 Issue 12, p1963 

    It was previously reported that cytokines and neurotoxins released from activated inflammatory cells induced the loss of projecting dopaminergic neurons in the substantia nigra, which triggered the pathogenesis of PD. The present study investigated the effect of treatment with...

  • Bee Venom and Its Component Apamin as Neuroprotective Agents in a Parkinson Disease Mouse Model. Alvarez-Fischer, Daniel; Noelker, Carmen; Vulinović, Franca; Grünewald, Anne; Chevarin, Caroline; Klein, Christine; Oertel, Wolfgang H.; Hirsch, Etienne C.; Michel, Patrick P.; Hartmann, Andreas // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Bee venom has recently been suggested to possess beneficial effects in the treatment of Parkinson disease (PD). For instance, it has been observed that bilateral acupoint stimulation of lower hind limbs with bee venom was protective in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine...

  • A DJ-1 Based Peptide Attenuates Dopaminergic Degeneration in Mice Models of Parkinson's Disease via Enhancing Nrf2. Lev, Nirit; Barhum, Yael; Ben-Zur, Tali; Aharony, Israel; Trifonov, Lena; Regev, Noa; Melamed, Eldad; Gruzman, Arie; Offen, Daniel // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Drugs currently used for treating Parkinson's disease patients provide symptomatic relief without altering the neurodegenerative process. Our aim was to examine the possibility of using DJ-1 (PARK7), as a novel therapeutic target for Parkinson's disease. We designed a short peptide, named ND-13....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics